A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma

NCT05355051 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin's Lymphoma

Interventions

DRUG: Azacytidine
DRUG: Pembrolizumab

Sponsor

M.D. Anderson Cancer Center